|
1
|
Lindholm A, McEwen J and Riis AP: Improved
postprandial glycemic control with insulin aspart. A randomized
double-blind cross-over trial in type 1 diabetes. Diabetes Care.
22:801–805. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson JH Jr, Brunelle RL, Koivisto VA,
et al: Reduction of postprandial hyperglycemia and frequency in
hypoglycemia in IDDM patients on insulin-analog treatment.
Multicenter Insulin Lispro Study Group. Diabetes. 46:265–270. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raskin P, Klaff L, Bergenstal R, et al: A
16-week comparison of the novel insulin analog insulin glargine
(HOE901) and NPH human insulin used with insulin lispro in patients
with type 1 diabetes. Diabetes Care. 23:1666–1671. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lepore M, Pampanelli S, Fanelli C, et al:
Pharmacokinetics and pharmacodynamics of subcutaneous injection of
long-acting human insulin analog glargine, NPH insulin, and
ultralente human insulin and continuous subcutaneous infusion of
insulin lispro. Diabetes. 49:2142–2148. 2000. View Article : Google Scholar
|
|
5
|
Pickup J and Keen H: Continuous
subcutaneous insulin infusion at 25 years: evidence base for the
expanding use of insulin pump therapy in type 1 diabetes. Diabetes
Care. 25:593–598. 2002.PubMed/NCBI
|
|
6
|
Reynolds LR: Reemergence of insulin pump
therapy in the 1990s. South Med J. 93:1157–1161. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bode BW, Steed RD and Davidson PC:
Reduction in severe hypoglycemia with long-term continuous
subcutaneous insulin infusion in type 1 diabetes. Diabetes Care.
19:324–327. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bode BW, Weinstein R, Bell D, et al:
Comparison of insulin aspart with buffered regular insulin and
insulin lispro in continuous subcutaneous insulin infusion: a
randomized study in type I diabetes. Diabetes Care. 25:439–444.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bode B and Strange P: Efficacy, safety,
and pump compatibility of insulin aspart used in continuous
subcutaneous insulin infusion therapy in patients with type 1
diabetes. Diabetes Care. 24:69–72. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsui E, Barnie A, Ross S, et al: Intensive
insulin therapy with insulin lispro: a randomized trial of
continuous subcutaneous insulin infusion versus multiple daily
insulin injection. Diabetes Care. 24:1722–1727. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Elbein SC, Wegner K and Kahn SE: Reduced
beta-cell compensation to the insulin resistance associated with
obesity in members of caucasian familial type 2 diabetic kindreds.
Diabetes Care. 23:221–227. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang W, Lu J, Weng J, et al; China
national Diabetes and Metabolic Disorders Study Group. Prevalence
of diabetes among men and women in China. N Engl J Med.
362:1090–1101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
An YL, Gao Y, Zhu Q, et al: Features of
insulin secretion and insulin resistance in newly diagnosed type 2
diabetes of different body mass indices. Zhonghua Yi Xue Za Zhi.
24:256–260. 2008.(In Chinese).
|
|
14
|
Juan CC, Fang VS, Kwok CF, et al:
Exogenous hyperinsulinemia causes insulin resistance,
hyperendothelinemia, and subsequent hypertension in rats.
Metabolism. 48:465–471. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bruttomesso D, Pianta A, Crazzolara D, et
al: Continuous subcutaneous insulin infusion (CSII) in the Veneto
region: efficacy, acceptability and quality of life. Diabet Med.
19:628–634. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weissberg-Benchell J, Antisdel-Lomaglio J
and Seshadri R: Insulin pump therapy: a meta-analysis. Diabetes
Care. 26:1079–1087. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bruttomesso D, Crazzolara D, Maran A, et
al: In Type 1 diabetic patients with good glycaemic control, blood
glucose variability is lower during continuous subcutaneous insulin
infusion than during multiple daily injections with insulin
glargine. Diabet Med. 25:326–332. 2008. View Article : Google Scholar
|
|
18
|
Jothydev Kesavadev J, Balakrishnan S,
Ahammed S and Jothydev S: Reduction of glycosylated hemoglobin
following 6 months of continuous subcutaneous insulin infusion in
an Indian population with type 2 diabetes. Diabetes Technol Ther.
11:517–21. 2009.PubMed/NCBI
|
|
19
|
Torres I, Ortego J, Valencia I, et al:
Benefits of continuous subcutaneous insulin infusion in type 1
diabetes previously treated with multiple daily injections with
once-daily glargine and pre-meal analogues. Exp Clin Endocrinol
Diabetes. 117:378–385. 2009. View Article : Google Scholar
|
|
20
|
Phillip M, Battelino T, Rodriguez H, et
al; European Society for Paediatric Endocrinology; Lawson Wilkins
Pediatric Endocrine Society; International Society for Pediatric
and Adolescent Diabetes; American Diabetes Association; European
Association for the Study of Diabetes. Use of insulin pump therapy
in the pediatric age-group: consensus statement from the European
Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric
Endocrine Society, and the International Society for Pediatric and
Adolescent Diabetes, endorsed by the American Diabetes Association
and the European Association for the Study of Diabetes. Diabetes
Care. 30:1653–1662. 2007.
|
|
21
|
Monami M, Lamanna C, Marchionni N and
Mannucci E: Continuous subcutaneous insulin infusion versus
multiple daily insulin injections in type 2 diabetes: a
meta-analysis. Exp Clin Endocrinol Diabetes. 117:220–222. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kesavadev J, Balakrishnan S, Ahammed S and
Jothydev S: Reduction of glycosylated hemoglobin following 6 months
of continuous subcutaneous insulin infusion in an Indian population
with type 2 diabetes. Diabetes Technol Ther. 11:517–521. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carotenuto M, Esposito M, Parisi L, et al:
Depressive symptoms and childhood sleep apnea syndrome.
Neuropsychiatr Dis Treat. 8:369–373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Verrotti A, Agostinelli S, D’Egidio C, et
al: Impact of a weight loss program on migraine in obese
adolescents. Eur J Neurol. 20:394–397. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carotenuto M, Santoro N, Grandone A, et
al: The insulin gene variable number of tandem repeats (INS VNTR)
genotype and sleep disordered breathing in childhood obesity. J
Endocrinol Invest. 32:752–755. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carotenuto M, Bruni O, Santoro N, et al:
Waist circumference predicts the occurrence of sleep-disordered
breathing in obese children and adolescents: a questionnaire-based
study. Sleep Med. 7:357–361. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hoogma RP, Hammond PJ, Gomis R, et al;
5-Nations Study Group. Comparison of the effects of continuous
subcutaneous insulin infusion (CSII) and NPH-based multiple daily
insulin injections (MDI) on glycaemic control and quality of life:
results of the 5-nations trial. Diabet Med. 23:141–147. 2006.
View Article : Google Scholar
|
|
28
|
Workgroup on Hypoglycemia, American
Diabetes Association. Defining and reporting hypoglycemia in
diabetes: a report from the American Diabetes Association Workgroup
on Hypoglycemia. Diabetes Care. 28:1245–1249. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marcovecchio ML, Lucantoni M and Chiarelli
F: Role of chronic and acute hyperglycemia in the development of
diabetes complications. Diabetes Technol Ther. 13:389–394. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ceriello A and Ihnat MA: ‘Glycaemic
variability’: a new therapeutic challenge in diabetes and the
critical care setting. Diabet Med. 27:862–867. 2010.
|
|
31
|
Bragd J, von Döbeln A, Lins PE, et al:
Basal insulin substitution with glargine or continuous subcutaneous
insulin infusion in adult type 1 diabetes patients-a randomized
controlled trial. Diabetes Technol Ther. 12:689–693. 2010.
View Article : Google Scholar
|
|
32
|
Tone A, Iseda I, Higuchi C, et al:
Comparison of insulin detemir and insulin glargine on glycemic
variability in patients with type 1 and type 2 diabetes. Exp Clin
Endocrinol Diabetes. 118:320–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Suzuki D, Toyoda M, Kondo M, et al:
Efficacy of long-acting insulin analog insulin glargine at high
dosage for basal-bolus insulin therapy in patients with type 2
diabetes. Tokai J Exp Clin Med. 37:35–40. 2012.PubMed/NCBI
|
|
34
|
Cai X, Han X, Luo Y and Ji L: Analysis of
insulin doses of Chinese type 2 diabetic patients with intensive
insulin treatment. PLoS One. 7:e389622012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kelley D, Mokan M and Veneman T: Impaired
postprandial glucose utilization in non-insulin-dependent diabetes
mellitus. Metabolism. 43:1549–1557. 1994. View Article : Google Scholar : PubMed/NCBI
|
